DaShenLin Pharmaceutical Group Co (SHSE:603233) Construction In Progress: ¥403 Mil (As of Mar. 2026)


SHSE:603233 DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
95 GF Score
Price ¥17.05
GF Value ¥18.74
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DaShenLin Pharmaceutical Group Co Construction In Progress?

DaShenLin Pharmaceutical Group Co SHSE:603233 +4.67% 95 Construction In Progress is ¥403 Mil as of Mar. 2026. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.74 (Fairly Valued). The stock has 4 warning signs investors should review.

DaShenLin Pharmaceutical Group Co's quarterly construction in progress declined from Sep. 2025 (¥372 Mil) to Dec. 2025 (¥359 Mil) but then increased from Dec. 2025 (¥359 Mil) to Mar. 2026 (¥403 Mil).

DaShenLin Pharmaceutical Group Co's annual construction in progress declined from Dec. 2023 (¥875 Mil) to Dec. 2024 (¥488 Mil) and declined from Dec. 2024 (¥488 Mil) to Dec. 2025 (¥359 Mil).

DaShenLin Pharmaceutical Group Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for DaShenLin Pharmaceutical Group Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaShenLin Pharmaceutical Group Co Construction In Progress Chart

DaShenLin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 765.67 1,049.09 874.53 487.75 358.57

DaShenLin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 522.41 341.79 371.52 358.57 402.82
SHSE:603233
95GF Score
DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DaShenLin Pharmaceutical Group Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥403 Mil mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Construction In Progress of ¥403 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on DaShenLin Pharmaceutical Group Co and its competitors.
Is DaShenLin Pharmaceutical Group Co's Construction In Progress too high?
DaShenLin Pharmaceutical Group Co's current Construction In Progress is ¥403 Mil. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Construction In Progress compare to competitors?
DaShenLin Pharmaceutical Group Co's Construction In Progress of ¥403 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Healthcare Providers & Services company?
A good Construction In Progress depends on the Healthcare Providers & Services industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. DaShenLin Pharmaceutical Group Co's current Construction In Progress is ¥403 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.74, compared to a current price of ¥17.05 — trading 9% below its estimated fair value. The current Construction In Progress is ¥403 Mil. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Construction In Progress is ¥403 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?

Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥17.05 is trading 9% below its estimated GF Value™ of ¥18.74. GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:603233:

  • Construction In Progress: ¥403 Mil
  • GF Value™: ¥18.74 vs. price of ¥17.05 (9% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaShenLin Pharmaceutical Group Co Business Description

Address No. 410-1, Longxi Avenue, Liwan District, Guangdong Province, Guangzhou, CHN, 510000
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score

Get the complete analysis for SHSE:603233

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.05
Price
¥18.74
GF Value